HSA Approves "Comirnaty" as the New Brand Name for Pfizer-BioNTech's COVID-19 Vaccine
The Health Sciences Authority (HSA) has on 14 September 2021 approved the application by Pfizer to introduce the branded version of its COVID-19 vaccine, Comirnaty, under the Pandemic Special Access Route. The Comirnaty COVID-19 Vaccine is manufactured according to the same processes as the Pfizer-BioNTech COVID-19 Vaccine, with the same efficacy and safety aspects. The only difference is the labelled name.
2 Singapore had received several batches of Comirnaty and the vaccines have been used in our national vaccination programme.
HEALTH SCIENCES AUTHORITY
SINGAPORE
14 SEPTEMBER 2021
Download pdf version here 638 KB
Consumer, Healthcare professional, Industry member, Therapeutic Products
Published:
HSA Updates